Company: CERO
Filing Date: 2025-06-16
Form Type: 424B3
Source: 0001213900-25-054769
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-16
Form: 424B3
Chunk 2
---
 of each exchange on which registered |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Capital Market                     |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
Act of 1934.

Emerging growth company ☒

If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June
11, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”)
to its Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse
stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

As previously
disclosed, at its 2025 Annual Meeting of Stockholders held on May 29, 2025 (the “Annual Meeting”), and upon the recommendation
of the Company’s Board of Directors (the “Board”), the Company’s stockholders approved a certificate of amendment
to effect a reverse stock split of the Common Stock at a ratio ranging from any whole number between 1-for-2 and 1-for-25, as determined
by the Board in its discretion, subject to the Board’s authority to abandon such amendment (the “Charter Amendment”).

The Charter
Amendment was described in detail under “Proposal No. 1: Reverse Stock Split Proposal” beginning on page 7 of the Company’s
definitive proxy statement filed with the Securities and Exchange Commission on May 7, 2025 (the “Proxy Statement”) in connection
with the Annual Meeting. The text of the Charter Amendment was included in Appendix A of the Proxy Statement.

On May
29, 2025, the Board approved a reverse stock split of the Common Stock at a ratio of